title: Involvement of nitric oxide in spinally mediated capsaicin- and glutamate-induced behavioural responses in the mouse.
abstract: The intrathecal (i.t.) injection of capsaicin (0.1 nmol/mouse) through a lumbar puncture elicited scratching, biting and licking responses. Pretreatment with the nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME) (320 nmol), by i.t. injection, resulted in a significant inhibition of the behavioural response produced by i.t. capsaicin (0.1 nmol/mouse). Similar behavioural responses were induced by i.t. injections of NMDA (0.4 nmol), kainate (0.05 nmol) or AMPA (0.05 nmol), which were all inhibited by co-administration of L-NAME (20-80 nmol). L-Arginine (600 mg/kg, i.p.) but not D-arginine (600 mg/kg, i.p.) reversed the inhibitory effect of L-NAME on capsaicin-, NMDA-, kainate- and AMPA-induced behavioural response. Scratching, biting and licking responses induced by tachykinin receptor agonists, substance P, [Sar9,Met(O2)11]substance P, neurokinin A and neurokinin B were not affected by co-administration of L-NAME (40 and 80 nmol). These results suggest that spinal nitric oxide may play a significant role in mechanisms of the behavioural response to capsaicin, probably through the release of glutamate, but not tachykinins.
authors.affiliation: Department of Biochemistry, Daiichi College of Pharmaceutical Sciences, Fukuoka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sakurada
authors.forename: A
authors.initials: A
authors.lastname: Sugiyama
authors.forename: C
authors.initials: C
authors.lastname: Sakurada
authors.forename: K
authors.initials: K
authors.lastname: Tanno
authors.forename: S
authors.initials: S
authors.lastname: Sakurada
authors.forename: K
authors.initials: K
authors.lastname: Kisara
authors.forename: A
authors.initials: A
authors.lastname: Hara
authors.forename: Y
authors.initials: Y
authors.lastname: Abiko
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002211:Capsaicin / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology; D018698:Glutamic Acid / Q000494:pharmacology*; D007278:Injections, Spinal; D007608:Kainic Acid / Q000494:pharmacology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D016202:N-Methylaspartate / Q000494:pharmacology; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000037:antagonists & inhibitors; D018039:Receptors, Tachykinin / Q000819:agonists; D013116:Spinal Cord / Q000187:drug effects / Q000502:physiology*; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D018690:Excitatory Amino Acid Agonists; D018039:Receptors, Tachykinin; D009569:Nitric Oxide; D018698:Glutamic Acid; D016202:N-Methylaspartate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; D019001:Nitric Oxide Synthase; D002211:Capsaicin; D007608:Kainic Acid; D019331:NG-Nitroarginine Methyl Ester